FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171873561> ?p ?o ?g. }

• W2171873561 endingPage "671" @default.
• W2171873561 startingPage "663" @default.
• W2171873561 abstract "Background More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings The signature has a performance, sensitivity, and specificity of 85·4% (95% CI 77·7–93·2), 84·4% (66·5–94·1), and 86·5% (81·1–90·6), respectively, to predict patient outcome. Multivariate analysis indicates that the signature is a significant independent predictor of overall survival and progression-free survival after controlling for currently used risk factors: patients with high molecular risk have a higher risk of death from disease and higher risk of relapse or progression than patients with low molecular risk (odds ratio 19·32 [95% CI 6·50–57·43] and 3·96 [1·97–7·97] for overall survival and progression-free survival, respectively, both p<0·0001). Patients at an increased risk of an adverse outcome can also be identified in the current treatment groups, showing the potential of this signature for improved clinical management. These results were confirmed in the validation study, in which the signature was also independently statistically significant in a model adjusted for MYCN status, age, International Neuroblastoma Staging System stage, ploidy, International Neuroblastoma Pathology Classification grade of differentiation, and mitosis karyorrhexis index (odds ratios between 4·81 and 10·53 depending on the model for overall survival and 3·68 [95% CI 2·01–6·71] for progression-free survival). Interpretation The 59-gene expression signature is an accurate predictor of outcome in patients with neuroblastoma. The signature is an independent risk predictor, identifying patients with an increased risk of poor outcome in the current clinical-risk groups. The method and signature is suitable for routine laboratory testing, and should be evaluated in prospective studies. Funding The Belgian Foundation Against Cancer, the Children Cancer Fund Ghent, the Belgian Society of Paediatric Haematology and Oncology, the Belgian Kid's Fund and the Fondation Nuovo-Soldati (JV), the Fund for Scientific Research Flanders (KDP, JH), the Fund for Scientific Research Flanders, the Institute for the Promotion of Innovation by Science and Technology in Flanders, Strategisch basisonderzoek, the Fondation Fournier Majoie pour l'Innovation, the Instituto Carlos III, the Italian Neuroblastoma Foundation, the European Community under the FP6, and the Belgian programme of Interuniversity Poles of Attraction." @default.
• W2171873561 created "2016-06-24" @default.
• W2171873561 creator A5000257053 @default.
• W2171873561 creator A5000459362 @default.
• W2171873561 creator A5003639088 @default.
• W2171873561 creator A5004924184 @default.
• W2171873561 creator A5008197312 @default.
• W2171873561 creator A5013471916 @default.
• W2171873561 creator A5015213142 @default.
• W2171873561 creator A5017362962 @default.
• W2171873561 creator A5020351421 @default.
• W2171873561 creator A5021414414 @default.
• W2171873561 creator A5027448217 @default.
• W2171873561 creator A5029619328 @default.
• W2171873561 creator A5030873065 @default.
• W2171873561 creator A5033742363 @default.
• W2171873561 creator A5036592214 @default.
• W2171873561 creator A5037699113 @default.
• W2171873561 creator A5039569312 @default.
• W2171873561 creator A5045426069 @default.
• W2171873561 creator A5047048269 @default.
• W2171873561 creator A5056038773 @default.
• W2171873561 creator A5058372540 @default.
• W2171873561 creator A5059398199 @default.
• W2171873561 creator A5059410021 @default.
• W2171873561 creator A5059413304 @default.
• W2171873561 creator A5060213422 @default.
• W2171873561 creator A5061265036 @default.
• W2171873561 creator A5061831442 @default.
• W2171873561 creator A5064325786 @default.
• W2171873561 creator A5067172585 @default.
• W2171873561 creator A5070400853 @default.
• W2171873561 creator A5072146290 @default.
• W2171873561 creator A5072347237 @default.
• W2171873561 creator A5076007276 @default.
• W2171873561 creator A5076275499 @default.
• W2171873561 creator A5086580140 @default.
• W2171873561 creator A5090452704 @default.
• W2171873561 date "2009-07-01" @default.
• W2171873561 modified "2023-09-29" @default.
• W2171873561 title "Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study" @default.
• W2171873561 cites W1966935624 @default.
• W2171873561 cites W1994937010 @default.
• W2171873561 cites W1996238852 @default.
• W2171873561 cites W2006090902 @default.
• W2171873561 cites W2023587649 @default.
• W2171873561 cites W2046783953 @default.
• W2171873561 cites W2072868135 @default.
• W2171873561 cites W2084001490 @default.
• W2171873561 cites W2084239992 @default.
• W2171873561 cites W2087446092 @default.
• W2171873561 cites W2102091738 @default.
• W2171873561 cites W2106713259 @default.
• W2171873561 cites W2110417418 @default.
• W2171873561 cites W2119176807 @default.
• W2171873561 cites W2121533951 @default.
• W2171873561 cites W2128560053 @default.
• W2171873561 cites W2128985829 @default.
• W2171873561 cites W2129963666 @default.
• W2171873561 cites W2136245178 @default.
• W2171873561 cites W2138550913 @default.
• W2171873561 cites W2147457741 @default.
• W2171873561 cites W2154273881 @default.
• W2171873561 cites W2160188982 @default.
• W2171873561 cites W2163563958 @default.
• W2171873561 cites W2164318029 @default.
• W2171873561 cites W2165151268 @default.
• W2171873561 cites W2166230389 @default.
• W2171873561 cites W2170140374 @default.
• W2171873561 cites W4211031423 @default.
• W2171873561 doi "https://doi.org/10.1016/s1470-2045(09)70154-8" @default.
• W2171873561 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3045079" @default.
• W2171873561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19515614" @default.
• W2171873561 hasPublicationYear "2009" @default.
• W2171873561 type Work @default.
• W2171873561 sameAs 2171873561 @default.
• W2171873561 citedByCount "171" @default.
• W2171873561 countsByYear W21718735612012 @default.
• W2171873561 countsByYear W21718735612013 @default.
• W2171873561 countsByYear W21718735612014 @default.
• W2171873561 countsByYear W21718735612015 @default.
• W2171873561 countsByYear W21718735612016 @default.
• W2171873561 countsByYear W21718735612017 @default.
• W2171873561 countsByYear W21718735612018 @default.
• W2171873561 countsByYear W21718735612019 @default.
• W2171873561 countsByYear W21718735612020 @default.
• W2171873561 countsByYear W21718735612021 @default.
• W2171873561 countsByYear W21718735612022 @default.
• W2171873561 countsByYear W21718735612023 @default.
• W2171873561 crossrefType "journal-article" @default.
• W2171873561 hasAuthorship W2171873561A5000257053 @default.
• W2171873561 hasAuthorship W2171873561A5000459362 @default.
• W2171873561 hasAuthorship W2171873561A5003639088 @default.
• W2171873561 hasAuthorship W2171873561A5004924184 @default.
• W2171873561 hasAuthorship W2171873561A5008197312 @default.
• W2171873561 hasAuthorship W2171873561A5013471916 @default.
• W2171873561 hasAuthorship W2171873561A5015213142 @default.
• W2171873561 hasAuthorship W2171873561A5017362962 @default.

• next